Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma
NCT07409246Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Nov 2031
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of ABBV-438 in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters and 2 more. Started Feb 2026; status: recruiting.
02
Drugs
ABBV-438
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07409246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409246.